|
1
|
Decastro GJ and McKiernan JM:
Epidemiology, clinical staging and presentation of renal cell
carcinoma. Urol Clin North Am. 35:581–592. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garcia JA, Cowey CL and Godley PA: Renal
cell carcinoma. Curr Opin Oncol. 21:266–271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Spronsen DJ, de Weijer KJ, Mulders PF
and De Mulder PH: Novel treatment strategies in clear-cell
metastatic renal cell carcinoma. Anticancer Drugs. 16:709–717.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Veldhuizen PJ, Hussey M, Lara PN Jr,
et al: A phase II study of gemcitabine and capecitabine in patients
with advanced renal cell cancer: Southwest Oncology Group Study
S0312. Am J Clin Oncol. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Escudier B, Eisen T, Stadler WM, et al:
TARGET Study Group: Sorafenib in advanced clear-cell renal-cell
carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motzer RJ, Michaelson MD, Rosenberg J, et
al: Sunitinib efficacy against advanced renal cell carcinoma. J
Urol. 178:1883–1887. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu CF, Bing NX, Ball HA, et al: Pazopanib
efficacy in renal cell carcinoma: evidence for predictive genetic
markers in angiogenesis-related and exposure-related genes. J Clin
Oncol. 29:2557–2564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cella D, Escudier B, Rini B, et al:
Patient-reported outcomes for axitinib vs sorafenib in metastatic
renal cell carcinoma: phase III (AXIS) trial. Br J Cancer.
108:1571–1578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Escudier B, Pluzanska A, Koralewski P, et
al: AVOREN Trial Investigators: Bevacizumab plus interferon alfa-2a
for treatment of metastatic renal cell carcinoma: a randomised,
double-blind phase III trial. Lancet. 370:2103–2111. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hudes G, Carducci M, Tomczak P, et al:
Temsirolimus, interferon alfa, or both for advanced renal-cell
carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Motzer RJ, Escudier B, Oudard S, et al:
Efficacy of everolimus in advanced renal cell carcinoma: a
double-blind, randomised, placebo-controlled phase III trial.
Lancet. 372:449–456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim HL, Belldegrun AS, Freitas DG, et al:
Paraneoplastic signs and symptoms of renal cell carcinoma:
implications for prognosis. J Urol. 170:1742–1746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Higgins JPT and Green S: Cochrane Handbook
for Systematic Reviews of Interventions. John Wiley … Sons, Inc;
Chichester, UK: 2008, View Article : Google Scholar
|
|
16
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Escudier B, Eisen T, Stadler WM, et al:
TARGET Study Group: Sorafenib in advanced clear-cell renal-cell
carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Escudier B, Szczylik C, Hutson TE, et al:
Randomized phase II trial of first-line treatment with sorafenib
versus interferon Alfa-2a in patients with metastatic renal cell
carcinoma. J Clin Oncol. 27:1280–1289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sternberg CN, Davis ID, Mardiak J, et al:
Pazopanib in locally advanced or metastatic renal cell carcinoma:
results of a randomized phase III trial. J Clin Oncol.
28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rini BI, Melichar B, Ueda T, et al:
Axitinib with or without dose titration for first-line metastatic
renal-cell carcinoma: a randomised double-blind phase 2 trial.
Lancet Oncol. 14:1233–1242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Overall survival and updated results for sunitinib compared with
interferon alfa in patients with metastatic renal cell carcinoma. J
Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Escudier B, Albiges L and Sonpavde G:
Optimal management of metastatic renal cell carcinoma: Current
status. Drugs. 73:427–438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maitland ML, Kasza KE, Karrison T, et al:
Ambulatory monitoring detects sorafenib-induced blood pressure
elevations on the first day of treatment. Clin Cancer Res.
15:6250–6257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rixe O, Bukowski RM, Michaelson MD, et al:
Axitinib treatment in patients with cytokine-bractory metastatic
renal-cell cancer: a phase II study. Lancet Oncol. 8:975–984. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rini BI, Quinn DI, Baum M, et al:
Hypertension among patients with renal cell carcinoma receiving
axitinib or sorafenib: analysis from the randomized phase III AXIS
trial. Target Oncol. 2014.PubMed/NCBI
|
|
27
|
Edmonds K, Hull D, Spencer-Shaw A, et al:
Strategies for assessing and managing the adverse events of
sorafenib and other targeted therapies in the treatment of renal
cell and hepatocellular carcinoma: recommendations from a European
nursing task group. Eur J Oncol Nurs. 16:172–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hutson TE, Figlin RA, Kuhn JG and Motzer
RJ: Targeted therapies for metastatic renal cell carcinoma: an
overview of toxicity and dosing strategies. Oncologist.
13:1084–1096. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
O'Brien BE, Kaklamani VG and Benson AB
III: The assessment and management of cancer treatment-related
diarrhea. Clin Colorectal Cancer. 4:375–381; discussion 382–373.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bellmunt J, Eisen T, Fishman M and Quinn
D: Experience with sorafenib and adverse event management. Crit Rev
Oncol Hematol. 78:24–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
La Vine DB, Coleman TA, Davis CH,
Carbonell CE and Davis WB: Frequent dose interruptions are required
for patients receiving oral kinase inhibitor therapy for advanced
renal cell carcinoma. Am J Clin Oncol. 33:217–220. 2010.PubMed/NCBI
|
|
32
|
Dutcher JP, Tannir N, Bellmunt J and
Escudier B: Experience with sorafenib and the elderly patient. Med
Oncol. 27:1359–1370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Benson AB III, Ajani JA, Catalano RB, et
al: Recommended guidelines for the treatment of cancer
treatment-induced diarrhea. J Clin Oncol. 22:2918–2926. 2004.
View Article : Google Scholar : PubMed/NCBI
|
